Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ultrasound technique may predict chemo response in breast cancer

NCT ID NCT02834494

Diagnosis Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a special 3D ultrasound technique, called shear wave elastography, can predict how well breast cancer responds to chemotherapy before surgery. Researchers measured tumor stiffness in 140 women with locally advanced breast cancer at several points during treatment. The goal was to see if changes in stiffness could accurately forecast the final response, potentially reducing the need for extra biopsies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
3D Shear Wave Elastography (ultrasound imaging)
What this could lead to
If successful, this imaging technique could help doctors quickly see if chemotherapy is working, allowing them to adjust treatment earlier.
What could go wrong
This is a completed observational study, not a treatment trial. The imaging method may not be accurate enough to replace standard biopsy or may not work for all tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

140 people

The number who actually took part.

Started

Feb 2016

Finished

Sep 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Infiltrating Breast Cancer untreated and/or locally advanced (stages I (T1c), IIa IIb, IIIa, IIIb, IIIc of UICC classification), whatever histological type. * Neo-adjuvant chemotherapy decided.(Anthracyclines, taxanes and, for tumors overexpressing human epidermal growth factor receptor 2 (HER2) protein, targeted recombinant humanized monoclonal antibodies) * Index tumor whose dimensions are between 10 to 50 mm. Multifocality, and/or multicentricity and/or bilaterality accepted (maximum 2 tumors by breast et tumors well differentiated from each other). * Patients aged at least 18 years old at diagnosis * Full results conventional breast exams available and no reason to achieve MRI breast exam * Patient explanation given and consent information signed Exclusion Criteria: * Pregnant or during lactation * Personal history of ipsilateral breast cancer (ipsilateral recurrence or second cancer in the same breast). * Patient carrier of cosmetic breast implants * Person deprived of liberty or under guardianship * Contraindication for receiving neo-adjuvant chemotherapy for any medical reason * Inability to submit to medical monitoring of the trial for reasons of geography, social or psychological.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast neoplasms

Contacts and locations

Locations

  • Institut Curie Paris

    Paris, 75005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.